Lisa Carey on Muck Rack

Lisa Carey

  • Owner, New Creative Media & Services LLC
Houston
As seen in: Color Research & Application, Nature, Wiley Online Library, JAMA (The Journal of the American Medical Association), The Irish Times, Medscape, The New England Journal of Medicine, RTE Brainstorm, Cell Reports Medicine, The Lancet and
mother, wife, friend and writer, @ycontributor, @yahooshine, @examinercom @moneysvgparent, @atozlearning, #parenting, #Momtrepreneur, #green, #YCN, #Houston #TV
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Lisa

Contact Lisa, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

88 Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer (ABC): A Subgroup Analysis in CDK4/6 Inhibitor (CDK4/6i)-Pretreated Patients From EMBER-3

|
By MPR Rate, Cristina Saura, Lisa Carey
| ONCOLOGY journal
Background Imlunestrant is a next-generation, brain-penetrant, oral SERD. The EMBER-3 trial reported significant progression-free survival (PFS) improvement with imlunestrant over standard therapy (SOC; fulvestrant or exemestane) in patients with ESR1 mutations, and with imlunestrant plus abemaciclib over imlunestrant in all patients, regardless of ESR1 mutation.
Open in Who Shared Issue with article?

Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial

|
By Joyce O’Shaughnessy, François-Clément Bidard, Patrick Neven, Mónica Casalnuovo, Philippe Aftimos, Cristina Saura, Nadia Harbeck, Lisa Carey, Giuseppe Curigliano, Jose A Garcia-Saenz, Maria Fernandez Abad, Larissa de Paula, Yeon Hee Park, Ozgur Ozyilkan, Maria Munoz, Maria Muñoz, Emily Barrett, Shanshan Cao, Aarti Chawla, Komal Jhaveri
| Nature
Abstract In EMBER-3 (NCT04975308), among patients with ER + , HER2- advanced breast cancer (ABC) with recurrence/progression on/after endocrine therapy (ET), imlunestrant significantly prolonged PFS versus standard ET in patients with ESR1 mutations, and imlunestrant + abemaciclib prolonged PFS versus imlunestrant in the overall population. We report the incidence, severity, timing, and management of common treatment-emergent adverse events (TEAEs), including safety profiles of select subgroups.
Open in Who Shared Issue with article?

Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer | NEJM

|
By Otto Metzger, Angela DeMichele, Lisa Carey
| buff.ly
Published January 28, 2026 N Engl J Med 2026;394:451-462 DOI: 10.1056/NEJMoa2511218 For permission requests, please contact NEJM Reprints at Are you a member of an institution such as a university or hospital?Learn more about Institutional Access Notes Presented in part at the 2024 San Antonio Breast Cancer Symposium.
Open in Who Shared Issue with article?
See all 571 licensed articles (574 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Lisa

Contact Lisa, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified